Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GW117 in major depressive disorder
NCT06796868Phase 2Completed
- Sponsor
- Beijing Greatway Pharmaceutical Technology Co., Ltd.
- Start
- Jul 2022
- Primary completion
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of GW117 in major depressive disorder (MDD), sponsored by Beijing Greatway Pharmaceutical Technology Co., Ltd.. Started Jul 2022; status: completed.
02
Drugs
GW117
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT06796868.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06796868.